Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial-Reference-Cited by-同舟云学术

Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial

Published:2018-05-21 Issue:7 Volume:58 Page:986-992
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Dodick David W.¹,Tepper Stewart J.²,Friedman Deborah I.,Gelfand Amy A.³,Kellerman Donald J.⁴,Schmidt Peter C.⁵

Affiliation:

1. Mayo Clinic, 5777 E Mayo Blvd; Phoenix AZ 85054 USA

2. Neurology Department; Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, One Medical Center Drive; Lebanon NH 03756 USA

3. University of California, San Francisco, 550 4th Street; San Francisco CA 94158 USA .

4. Zosano Pharma, 34790 Ardentech Court; Fremont CA 94555 USA

5. UT Southwestern Medical Center, 5323 Harry Hines Blvd; Dallas TX 75390 USA

Funder

Zosano Pharma

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/head.13327/fullpdf

Reference7 articles.